Johnson Clark T, Adami Rebecca R, Farzin Azadeh
Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Front Pharmacol. 2017 Mar 14;8:97. doi: 10.3389/fphar.2017.00097. eCollection 2017.
Chorioamnionitis is associated with significant maternal and neonatal morbidity and mortality throughout the world. In developed countries, great progress has been made to minimize the impact of chorioamnionitis, through timely diagnosis and appropriate treatment. In the global setting, where many women deliver outside the healthcare facilities, this diagnosis is frequently overlooked and not properly treated. In addition to its impact on maternal health, a significant proportion of neonatal morbidity and mortality can be prevented by both recognition and access to readily available treatment. With the increasing focus on saving the most vulnerable members of society, we echo the need for providing parturient women with suspected chorioamnionitis universal access to appropriate therapy. We describe known effective antibiotic therapies for chorioamnionitis and provide an overview of additional potential antimicrobial treatments that might be effectively implemented in areas with limited access to care.
在全球范围内,绒毛膜羊膜炎与孕产妇和新生儿的高发病率及死亡率相关。在发达国家,通过及时诊断和适当治疗,在将绒毛膜羊膜炎的影响降至最低方面已取得了巨大进展。在全球范围内,许多妇女在医疗机构之外分娩,这种诊断常常被忽视且未得到妥善治疗。除了对孕产妇健康的影响外,通过识别和获得现成的治疗,很大一部分新生儿发病率和死亡率是可以预防的。随着对拯救社会最弱势群体的日益关注,我们赞同应为疑似绒毛膜羊膜炎的产妇提供普遍获得适当治疗的机会。我们描述了已知的治疗绒毛膜羊膜炎的有效抗生素疗法,并概述了在医疗服务可及性有限的地区可能有效实施的其他潜在抗菌治疗方法。